IceCure Medical Ltd. (NASDAQ: ICCM)

IceCure Medical Ltd., a company that trades under the symbol ICCM, is a commercial stage medical device company operating in the healthcare industry. The company specializes in the development and marketing of cryoablation systems for the treatment of benign and malignant tumors. This minimally invasive alternative to surgical intervention offers a less traumatic and more affordable treatment option for patients.

IceCure Medical's main business activities revolve around the development and marketing of its cryoablation technology. This technology is used to treat various types of tumors, including breast, lung, and kidney tumors. The company's proprietary technology is a minimally invasive alternative to surgical intervention, offering a less traumatic and more affordable treatment option for patients. IceCure Medical operates in various countries, including the United States, Europe, China, Japan, Hong Kong, and Israel, among others.

The company generates revenue through the sale of single-use probes and disposables to distributors and end-users. Additionally, it places its systems under end-user commitments to purchase a minimum number of disposable probes per month and an annual service fee. IceCure Medical's primary products include its ProSense system, a single probe system that has received regulatory approvals in various countries. This system uses liquid nitrogen to freeze tumors, destroying cancer cells while preserving healthy tissue. The company is also developing its next-generation MultiSense system, which has the ability to freeze multiple tumors simultaneously or larger tumors.

IceCure Medical's competitive position in the medical device market is strong, with a growing presence in the interventional oncology space. The company's proprietary cryoablation technology and innovative products have the potential to disrupt the traditional surgical and heat-based ablation markets, offering a more effective and less invasive treatment option for patients. The company's key competitors include those in the medical device industry who may have greater financial and marketing resources. However, IceCure Medical's focus on proprietary technology and innovative products sets it apart from its competitors.

The company's customers include hospitals, clinics, and research institutions in various countries, including Kameda Medical Center in Kamogawa, Japan, Queen Mary Medical Center in Hong Kong, and Bnei Zion Medical Center in Haifa, Israel.

IceCure Medical's lead indication is breast tumors, which are the most common type of cancer among American women. The company has sponsored and completed a prospective clinical trial in benign breast tumors, demonstrating the effectiveness of its cryoablation technology in reducing tumor volume, palpability, pain, and improving cosmetic results. Additionally, the company is conducting a multi-site clinical trial in the United States to support FDA approval for the treatment of malignant breast tumors.

In addition to breast tumors, IceCure Medical is also developing its cryoablation technology for the treatment of lung, kidney, and other types of tumors. The company has conducted clinical trials in these indications and has presented promising results. For instance, the company has conducted a clinical trial in cryoablation of lung tumors in non-small cell carcinoma or metastatic lesions at the Kameda Medical Center in Kamogawa, Japan. The trial has shown promising results, with a 3-year recurrence-free survival rate of 73% for all tumors and 96% and 46% in tumors <2.2 cm and ≥ 2.2 cm, respectively.

In terms of intellectual property, IceCure Medical has a portfolio of 30 issued patents, as well as one patent application pending. The company's patents cover a range of technologies, including cryosurgical instruments, cryogenic pumps, and phase separation of cryogen in cryosurgical instruments.